the Business Model as Top-Line
strategies is Big
Pharma employing to enhance productivity and reduce costs in line with
slowing top-line growth?
R&D and portfolio optimization strategies are being pursued?
enhanced focus on oncology, what changes do you expect in the
regulatory, pricing and reimbursement environment for products in this
have many Big Pharma companies stayed “pure plays”
while others seek to diversify away from branded Rx drugs?
the business model for small/mid-size biotechnology companies changed
materially given current regulatory and pricing environment?
DEVICES PANEL “Growth Prospects
& Opportunities in an Increasingly Challenging Regulatory
& Competitive Environment”
are the relative growth prospects for the major segments within the
medical device industry (interventional cardiology, orthopedics,
is the changing regulatory and pricing/reimbursement environment in the
medical device industry affecting the launch of new products?
has the business model for early-stage device companies changed given
the current environment?
is the relationship between physician/surgeon and company sales
representatives evolving in orthopedics and other medical device
areas represent the greatest opportunity for
“convergence” between devices/ diagnostics and
Paradigms in Managing Costs/ Outcomes –
Impact of November Elections”
Which strategies are employers, insurers and providers pursuing to slow
the growth of employee healthcare costs and improve health outcomes?
• What actions are major
hospitals taking to reduce medical errors and improve outcomes?
• How effective have
consumer-driven healthcare initiatives been?
• Why is the healthcare
industry slow to adopt information technology, and what can be done to
overcome such barriers?
How will the November election affect potential legislation impacting
the cost and provision of care in the US?
AND ACQUISITIONS PANEL “Dealmaking
Strategies to Enhance Competitive Position”
is the likelihood of further transforming Big Pharma mergers? Will “pure
play” Big Pharma companies seek to diversify into other
businesses through large-scale acquisitions?
we continue to see Big Pharma buying biotech – using what
criteria and deal parameters?
sectors of the medical device and diagnostics area will experience the
greatest M&A activity and why?
you expect further consolidation among providers and payors? Which other healthcare
service areas are primed for enhanced M&A activity and why?
are private equity firms’ current investment strategies in
the healthcare sector?
are successful companies organized to best identify, pursue, negotiate,
and execute M&A and other business development initiatives?
SCIENCES VENTURES PANEL “Current
Strategies and Models for Life Science Venture Firms and
are the current investment strategies of life science venture capital
the recent decline in funding “idea companies” a
short-term phenomenon or fundamental change in strategy?
do corporate and VC firms differ in their respective focus and approach?
have exit options changed given current disruption in the capital
are some of the “lessons learned” from life science
entrepreneurs in building successful early-stage biotechnology and
medical device companies?
MARKETS PANEL “Opportunities
and Challenges for Global Healthcare Companies in BRIC and Other
are the opportunities & challenges of investing in, and
marketing to, BRIC countries (Brazil,
and other emerging markets for global healthcare companies?
the potential to enter these markets worth the risk to intellectual
what extent do global healthcare companies have a responsibility for
addressing global health challenges (AIDS, TB, malaria, etc.)?
is the record of success of public-private partnerships in combating
disease in developing countries?
STRATEGIES PANEL “Current Hiring/Talent
Deployment Needs of Leading Healthcare Companies and Career
is the current hiring environment for key segments of the healthcare
industry (pharma, med tech, payor/provider, healthcare consulting,
investment banking, etc.)?
is the likely hiring environment for MBAs (in healthcare) in 2009?
are leading healthcare companies maximizing the value of leadership
are the key professional and personal characteristics leading
healthcare companies are seeking in experienced new hires?
should employees respond to dislocations caused by cost reduction
programs, acquisitions, etc.?